权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of monitoring indicators for fatigue management in breast cancer patients undergoing outpatient chemotherapy

乳腺癌门诊化疗患者疲劳管理监测指标的制定

基本信息

批准号：
21792236
负责人：
FUKUDA Hiromi
金额：
$ 2.66万
依托单位：
Oita University of Nursing and Health Sciences
依托单位国家：
日本
项目类别：
Grant-in-Aid for Young Scientists (B)
财政年份：
2009
资助国家：
日本
起止时间：
2009 至 2010
项目状态：
已结题

项目摘要

Fatigue is one of the most common symptoms in breast cancer patients undergoing outpatient chemotherapy. The purpose of the present study was to examine the usefulness of urinary cytokines as indicators of fatigue including subjective fatigue. Factors affecting fatigue were clarified, and appropriate timing and methods of intervention for fatigue were considered. The present study investigated the first course of chemotherapy in breast cancer patients being treated with one of epirubicin / cyclophosphamide (EC), chemotherapy. 5-fluorouracil / epirubicin / cyclophosphamide (FEC), and taxotere / cyclophosphamide (TC) as a postoperative chemotherapy regimen. The percentage of subjects whose urinary cytokine levels were measurable was 40% for interleukin (IL)-1beta, 40% for IL-8, and 60% for tumor necrosis factor (TNF)-alpha. Comparison of cytokine levels before treatment and seven to ten days after the initiation of treatment revealed a significant difference in TNF-alpha levels before to … More after administration of EC. Other chemotherapy treatments yielded no statistically significant differences in cytokine levels before to after treatment. In addition, subjective fatigue and other symptoms were investigated using the Common Terminology Criteria for Adverse Events v3.0 Japanese JCOG/JSCO version. The severity of other symptoms including fatigue was grade 1 or less in 60-80% of the subjects in all of the postoperative chemotherapy regimens. In addition, subjects with symptom severity of grade 2 or 3 at the initiation of treatment exhibited improvement of symptoms during the course of treatment. Among factors affecting fatigue, subjects had poor appetite, nausea, difficulty in sleeping, pain, anxiety, depression, and related symptoms after the start of treatment, though the symptoms varied depending on the type and course of treatment. Furthermore, in FEC therapy, cytokine levels exhibited significant correlations with anxiety and depression, suggesting an association between them and symptoms affecting fatigue. Coping with fatigue in breast cancer patients undergoing outpatient chemotherapy requires fatigue support based on the type and timing of treatment. Less

疲劳是接受门诊化疗的乳腺癌患者最常见的症状之一。本研究的目的是检查尿细胞因子作为疲劳（包括主观疲劳）指标的有用性。阐明了影响疲劳的因素，并考虑了干预疲劳的适当时机和方法。本研究调查了接受表阿霉素/环磷酰胺（EC）化疗的乳腺癌患者的第一个化疗疗程。5-氟尿嘧啶/表阿霉素/环磷酰胺（FEC）和泰索帝/环磷酰胺（TC）作为术后化疗方案。尿细胞因子水平可测量的受试者百分比为：白细胞介素（IL）-1 β 40%，IL-8 40%，肿瘤坏死因子（TNF）-α 60%。比较治疗前和治疗开始后7 - 10天的细胞因子水平，发现治疗前和治疗开始后7 - 10天的TNF-α水平有显著差异。 ...更多信息服用EC后。其他化疗治疗前后细胞因子水平无统计学显著差异。此外，使用不良事件通用术语标准v3.0日本JCOG/JSCO版本研究主观疲劳和其他症状。在所有术后化疗方案中，60-80%的受试者的其他症状（包括疲劳）的严重程度为1级或更低。此外，治疗开始时症状严重程度为2级或3级的受试者在治疗过程中表现出症状改善。在影响疲劳的因素中，受试者在治疗开始后出现食欲不振、恶心、睡眠困难、疼痛、焦虑、抑郁和相关症状，尽管症状因治疗类型和疗程而异。此外，在FEC治疗中，细胞因子水平与焦虑和抑郁表现出显着的相关性，表明它们与影响疲劳的症状之间的关联。应对接受门诊化疗的乳腺癌患者的疲劳需要基于治疗类型和时间的疲劳支持。少